Pattern Pharma Inc.

[Available On-Demand]
Search General Info
Search Education
Search Partnering Companies
Pattern Pharma's P2PAR product activates the innate immune system (dendritic cells, macrophages & NK cells) and thereafter the adaptive immune system (via in situ vaccination), to address infectious diseases and cancers.
P2PAR has a newly issued US patent & is the next generation of an earlier product which has already received regulatory approval in an ex-US jurisdiction, where it has proven safe & efficacious during widespread use in several indications.
Pattern collaborates with the Massachusetts General Hospital, McGill University, the National Research Council of Canada & other institutions on its preclinical and clinical development. The overall P2PAR program has been the subject of a number of publications in leading peer-reviewed journals.
Based on supporting preclinical and human safety & efficacy data, as well as P2PAR’s well understood Mechanism of Action & immune correlates, Pattern now intends moving into the clinic in order to assess its efficacy against COVID-19.
Company Type:
Company Website:
Company HQ State:
Ontario
Company HQ Country:
Canada
Year Founded:
2018
Main Therapeutic Focus:
Lead Product in Development:
P2PAR
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
1
Speaker
photo
CEO
Pattern Pharma Inc.